Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 937-968

  Pan, Shu Ting ^a   Zhou, Zhi Wei ^b,c   He, Zhi Xu ^c   Zhang, Xueji ^d   Yang, Tianxin ^e   Yang, Yin Xue ^f   Wang, Dong ^g   Qiu, Jia Xuan ^a   Zhou, Shu Feng ^b  

^a NANCHANG UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NINGXIA MEDICAL UNIVERSITY   (China)

^g THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; Cell cycle; DMXAA; Non small cell lung cancer; SILAC

Indexed keywords

ADENYLATE KINASE; ALPHA TUBULIN; AMINO ACID; BECLIN 1; CARBOPLATIN; CATHEPSIN D; COFILIN 2; HIGH MOBILITY GROUP B1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MANGANESE SUPEROXIDE DISMUTASE; MICROTUBULE ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; NEURON SPECIFIC ENOLASE; PACLITAXEL; PEROXIREDOXIN 3; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHOGLUCONATE DEHYDROGENASE; PROSTAGLANDIN E SYNTHASE; REACTIVE OXYGEN METABOLITE; RECOMBINANT SOMATOMEDIN C; RIBOPHORIN I; S6 KINASE; TALIN; TRANSCRIPTION FACTOR NRF2; TRANSKETOLASE; TROPOMYOSIN; VADIMEZAN; VASCULOTROPIN; ZYXIN; ANTINEOPLASTIC AGENT; PROTEOME; TUMOR PROTEIN; XANTHONE DERIVATIVE;

AMINO ACID METABOLISM; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER MORTALITY; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; ISOTOPE LABELING; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEIC ACID METABOLISM; OXIDATION REDUCTION STATE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STABLE ISOTOPE LABELING BY AMINO ACIDS IN CELL CULTURE; SURVIVAL TIME; UPREGULATION; VOLUME OF DISTRIBUTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMISTRY; DRUG EFFECTS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; ISOTOPE LABELING; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XANTHONES;

EID: 84923207133     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S76021     Document Type: Article

References (74)

1. Siegel R, Desantis C, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed December 10, 2014.
3. US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta, GA, USA: Department of Health and Human Services, Centers for Disease Control and Prevention, National Cancer Institute; 2014. Available from: http://www.cdc.gov/cancer/npcr/pdf/USCS_FactSheet.pdf. Accessed December 10, 2014.
4. American Cancer Society. Cancer Facts and Figures 2014. Atlanta, GA, USA: American Cancer Society; 2014. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed December 10, 2014.
5. Wang YC, Wei LJ, Liu JT, Li SX, Wang QS. Comparison of Cancer Incidence between China and the USA. Cancer Biol Med. 2012;9(2):128–32.
6. Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol. 2013;10(6):334–343.
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
8. Brown SL, Kolozsvary A, Kim JH. Vascular targeting therapies for treatment of malignant disease. Cancer. 2005;104(1):216–217.
9. Amir E, Mandoky L, Blackhall F, et al. Antivascular agents for non-small-cell lung cancer: current status and future directions. Expert Opin Investig Drugs. 2009;18(11):1667–1686.
10. Zhou S, Kestell P, Baguley BC, Paxton JW. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs. 2002;20(3):281–295.
11. Buchanan CM, Shih JH, Astin JW, et al. DMXAA (vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. Clin Sci (Lond). 2012;122(10):449–457.
12. Li J, Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clin Cancer Res. 2008;14(7):2102–2110.
13. Zhou S, Paxton JW, Tingle MD, Kestell P. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos. 2000;28(12):1449–1456.
14. Miners JO, Valente L, Lillywhite KJ, et al. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res. 1997;57(2):284–289.
15. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 2008;99(12):2006–2012.
16. Lara PN Jr, Douillard JY, Nakagawa K, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(22):2965–2971.
17. Pili R, Rosenthal MA, Mainwaring PN, et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res. 2010;16(10): 2906–2914.
18. Fruh M, Cathomas R, Siano M, et al. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer. 2013;14(1):34–39.
19. Hida T, Tamiya M, Nishio M, et al. Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer Sci. 2011;102(4):845–851.
20. McKeage MJ, Reck M, Jameson MB, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer. 2009;65(2):192–197.
21. Prantner D, Perkins DJ, Lai W, et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem. 2012;287(47):39776–39788.
22. Conlon J, Burdette DL, Sharma S, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol. 2013;190(10): 5216–5225.
23. Gao P, Zillinger T, Wang W, et al. Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA. Cell Rep. 2014;8(6):1668–1676.
24. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 2013;138(2):255–271.
25. Ong SE, Mann M. Stable isotope labeling by amino acids in cell culture for quantitative proteomics. Methods Mol Biol. 2007;359:37–52.
26. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006;7(12):952–958.
27. Ong SE. The expanding field of SILAC. Anal Bioanal Chem. 2012;404(4):967–976.
28. Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc. 2006;1(6):2650–2660.
29. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.
30. Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014; 15(2):81–94.
31. Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol. 2013;53:89–106.
32. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16(8):797–803.
33. Wu WK, Coffelt SB, Cho CH. The autophagic paradox in cancer therapy. Oncogene. 2012;31(8):939–953.
34. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res. 2002;8(7):2024–2034.
35. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9(6):447–464.
36. Heavey S, O’Byrne KJ, Gately K. Strategies for co-targeting the PI3K/Akt/mTOR pathway in NSCLC. Cancer Treat Rev. 2014;40(3): 445–456.
37. Ellis L, Shah P, Hammers H, et al. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther. 2012; 11(2):383–392.
38. Brauer R, Wang LC, Woon ST, et al. Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. Neoplasia. 2010;12(9): 755–765.
39. Keum YS, Choi BY. Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway. Molecules. 2014;19(7):10074–10089.
40. Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
41. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–241.
42. Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157–183.
43. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571–580.
44. Maiuri MC, Criollo A, Kroemer G. Crosstalk between apoptosis and autophagy within the Beclin 1 interactome. EMBO J. 2010;29(3): 515–516.
45. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720–5728.
46. Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2′3′-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014;9(6):e99988.
47. Zhang SH, Zhang Y, Shen J, et al. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase. J Thromb Haemost. 2013;11(10):1855–1866.
48. Kim S, Peshkin L, Mitchison TJ. Vascular disrupting agent drug classes differ in effects on the cytoskeleton. PLoS One. 2012;7(7):e40177.
49. Shirey KA, Nhu QM, Yim KC, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-β-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011;89(3):351–357.
50. Woon ST, Hung SS, Wu DC, et al. NF-κB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Res. 2007;27(1A):327–334.
51. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004;100(12):2491–2499.
52. Dolai S, Xu Q, Liu F, Molloy MP. Quantitative chemical proteomics in small-scale culture of phorbol ester stimulated basal breast cancer cells. Proteomics. 2011;11(13):2683–2692.
53. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods. 2010; 7(5):383–385.
54. Everley PA, Krijgsveld J, Zetter BR, Gygi SP. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics. 2004;3(7): 729–735.
55. Doherty MK, Hammond DE, Clague MJ, Gaskell SJ, Beynon RJ. Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res. 2009;8(1): 104–112.
56. Hammond DE, Hyde R, Kratchmarova I, Beynon RJ, Blagoev B, Clague MJ. Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. J Proteome Res. 2010;9(5):2734–2742.
57. Duan X, Kelsen SG, Clarkson AB Jr, Ji R, Merali S. SILAC analysis of oxidative stress-mediated proteins in human pneumocytes: new role for treacle. Proteomics. 2010;10(11):2165–2174.
58. Coombs KM, Berard A, Xu W, et al. Quantitative proteomic analyses of influenza virus-infected cultured human lung cells. J Virol. 2010;84(20):10888–10906.
59. Munday DC, Hiscox JA, Barr JN. Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus subgroup B using SILAC coupled to LC-MS/MS. Proteomics. 2010; 10(23):4320–4334.
60. Foster MW, Thompson JW, Forrester MT, et al. Proteomic analysis of the NOS2 interactome in human airway epithelial cells. Nitric Oxide. 2013;34:37–46.
61. Wu Q, Xu W, Cao L, et al. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 cells. J Proteome Res. 2013;12(9):4064–4073.
62. Chiu HC, Hannemann H, Heesom KJ, Matthews DA, Davidson AD. High-throughput quantitative proteomic analysis of dengue virus type 2 infected A549 cells. PLoS One. 2014;9(3):e93305.
63. Gray TA, Alsamman K, Murray E, Sims AH, Hupp TR. Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2. Mol Biosyst. 2014; 10(6):1409–1425.
64. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393): 1497–1501.
65. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995;80(2):225–236.
66. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol. 2003; 5(12):1051–1061.
67. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275(5303):1129–1132.
68. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4(4):321–328.
69. Fesik SW, Shi Y. Structural biology. Controlling the caspases. Science. 2001;294(5546):1477–1478.
70. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717–1721.
71. Chen Y, Yu L. Autophagic lysosome reformation. Exp Cell Res. 2013;319(2):142–146.
72. Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 2012;19(1):87–95.
73. Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 2013;34(6):340–346.
74. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116.